TRACERx/PEACE: 501 samples from 24 #NSCLC pts (diagnosis→autopsy) reveal the metastatic cascade. Each met harbors a median of 7 subclones; 60% of mets seeded by OTHER mets (not primary); CIN drives extrathoracic spread. Single met biopsies massively underestimate disease complexity

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab url: aacrjournals.org/cancerdiscov...

💫 Best of #ELCC26 #gotistobart — novel pH-sensitive anti-CTLA-4 antibody that selectively depletes intratumoral Tregs — vs docetaxel in metastatic sqNSCLC after anti-PD-(L)1 + platinum: → Median OS: not reached vs 10 months 12mOS: 63vs30% (HR 0.46) → ORR: 20% vs 4.8% → Manageable safety profile

🕐 more about #time-of-day and ICI 📋 IPD meta-analysis across 8 Roche/atezolizumab RCTs (n=3,060 #lung cancer pts). First 2 ICI cycles administered before vs. after 12:00 pm 🎯 OS HR late vs early: 1.039 (95% CI 0.925–1.168) → Upper limit < 1.18: non-inferiority demonstrated ✅ #ELCC2026

#AI on routine CT scans quantifies thymic health → predicts ICI outcomes in 3,476 patients across NSCLC, melanoma, renal & breast cancer — independent of PD-L1 and TMB. Healthy thymus → ↑ TCR diversity → ↑ ICI efficacy. 🫁 #Immunotherapy #LungCancer #LCSM

Thymic health and immunotherapy outcomes in patients with cancer - Nature

A deep-learning approach applied to routine CT scans is used to quantify the health of the thymus in a cohort of patients with cancer, and shows that thymic function is associated with immunotherapy&n...

nature.com

MTAP loss has highest rates in ALK+ (up to 45%), followed by RET+ (up to 36%) and EGFR+ (up to 24%) NSCLC IHC and NGS may be complementary for detection. #PRMT5i shows activity PRMT5i + targeted therapy may outperform monotherapy in models www.annalsofoncology.org/article/S092...

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies

Homozygous loss of MTAP (methylthioadenosine phosphorylase) occurs in approximately 15% of cancers and leads to partial PRMT5 inhibition, creating a selective vulnerability to PRMT5 inhibitors. The fr...

annalsofoncology.org

HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial: Cancer Cell www.cell.com/cancer-cell/... In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%)

HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial

Wang et al. conducted an open-label, multicenter phase 1a/b study to evaluate the safety, pharmacokinetics, and efficacy of HS-20093 in patients with advanced solid tumors. HS-20093 demonstrated a man...

cell.com

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors - ESMO Open www.esmoopen.com/article/S205...

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Combining radiotherapy (RT) with targeted agents may lead to improved treatment outcomes across various tumor types. However, there is a risk of increased toxicity. Unfortunately, high-quality toxicit...

esmoopen.com

Heads or the Tail? | New England Journal of Medicine www.nejm.org/doi/full/10....

Heads or the Tail? | NEJM

Survival in patients with cancer, affected by myriad factors, is notoriously difficult to predict. But while oncologists find it hard to communicate the uncertainty, patients are the ones who must ...

nejm.org

Case series detailing immune checkpoint inhibitor related encephalitis (lung cancer, SCC, melanoma, lymphomas…). Most recovered with therapy academic.oup.com/oncolo/artic... In my experience, io-related encephalitis in mesothelioma are more dangerous

Immune-related encephalitis after immune checkpoint inhibitor therapy

Immune checkpoint inhibitors have revolutionized cancer treatment but can trigger immune-related encephalitis. This article reports one of the largest case

academic.oup.com

15% of LUAD lacked TTF-1 expression -> lower PD-L1 & more frequent KRAS and high-risk mutations, such as STK11, KEAP1, & SMARCA4 -> TTF-1 negativity stratified outcomes even among pts with high-risk mutations

Selective RET inhibitors: Non-KIF5B → better PFS (17.0 vs 5.5 months)

RET Fusion–Positive lung Adenocarcinoma: Partner-Specific clinicopathological Characteristics, co-mutation Profiles, and Implications for targeted and Immunotherapy

Rearranged during transfection (RET) gene fusions are rare but actionable oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in approximately 1.0%–2% of cases and predominantly in lung...

lungcancerjournal.info

Too good to be true?

Johannes Schwenke@schwenkej.bsky.social · 6mo ago

I would encourage people to check out the version control of this study on clinicaltrials.gov/study/NCT055.... The definition of early vs late, sample size, and inclusion criteria changed throughout the study period. Once it was even changed to be an observational study and then back to RCT??!

Interesting hypothesis about anti-TIGIT failure “Selecting an unmutated IgG1 targeting TIGIT, LAG-3, TIM-3, or PD-1 may deplete effector T cells through CDC, ADCC, and/or ADCP, thereby counteracting anticancer efficacy” #lcsm #tigit

Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies

ascopubs.org

In long-term responders to 2y first-line ICB, PET/CT-guided Tx discontinuation was associated with improved OS vs continued therapy, HR 0.35 Re-biopsy identified frequent second primary lung cancers and distinct resistance biology ➡️ local management #lungcancer #NSCLC #immunotherapy #ICI #PETCT

This is huge. Time of the day has an enormous impact on #immunotherapy outcome Early immunochemo (<15:00) vs late: 📈 mPFS: 11.3 vs 5.7 mo (HR 0.40) ⏳ mOS: 28.0 vs 16.8 mo (HR 0.42) 🧬 ↑ CD8⁺ activation | similar safety www.nature.com/articles/s41... #lcsm #nsclc

ascopubs.org/doi/10.1200/...

#Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with #EGFR-mutated #NSCLC: Pooled analysis of phase 1 and phase 2 trials www.annalsofoncology.org/article/S092...

Prof Xiuning Le from MDACC on EGFR PACC mutation #LCSM #EGFR #NSCLC #uncommonEGFR

www.jtocrr.org/article/S266... #lcsm #nsclc #zongertinib #tdxd #lungcancer

#ARTICUNO study 📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib 🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms 🔎 #E709 mut->lack of benefit #LCSM www.sciencedirect.com/science/arti...

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth fact…

sciencedirect.com

BOYCOTT USA NOW!!! It's time for all countries to stop doing business with this fascist country!! Enough with the blackmailing and intimidations!!!

MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA chuffed.org/project/1406...

MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA

MISSIONE INTERNAZIONALE – SALPIAMO PER GAZAMentre il genocidio in corso a Gaza peggiora di giorno in giorno e le istituzioni restano in silenzio, persone da tutto il mondo si stanno mobilitando per co...

chuffed.org

A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib. More effort is needed to manage toxicity. #ELCC2025

Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) - Journal of Thoracic Oncology www.jto.org/article/S155...

#Ivonescimab versus #pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China www.thelancet.com/journals/lan...

PFS≥12 on #durvalumab might be a positive predictive factor for ICB re-treatment #nsclc #lcsm www.ejcancer.com/article/S095...

Comparative Efficacy of Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab

The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patie...

ejcancer.com

🔥Annals of Oncology🆙 ✅Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer? 🎯Performing biopsies at treatment resistance is crucial to aid drug development 👥Drs. Jordi Remon and Stephanie Saw #LCSM @oncoalert.bsky.social #EGFR www.annalsofoncology.org/article/S092...

Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?

For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), overexpression of c-MET has been associated with resistance to EGFR tyrosine kinase inhibitors (TKIs). Upon prog...

annalsofoncology.org

Hidehito HORINOUCHI@hhorinouchi.bsky.social · 2y ago

🔥Annals of Oncology🆙 ✅Phase 1b study of telisotuzumab vedotin + osimertinib in pts with c-Met overexpressing, EGFR-m NSCLC after progression on prior osi 🎯MET ADC 🎯ORR 50.0%, mPFS 7.4 mo per ICR 👥 @hhorinouchi.bsky.social #LCSM @oncoalert.bsky.social #EGFR www.annalsofoncology.org/article/S092...

Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months. www.jnj.com/media-center...

How to reduce skin toxicity from #amivantamab #lazertinib in #NSCLC? 📝 oral antibiotic (doxycycline or minocycline) twice daily for 12 weeks 💊, then topical antibiotic (clindamycin 1 percent), antibacterial wash (chlorhexidine 4 percent), and daily ceramides-based noncomedogenic moisturizer 🧴